Abide is a biotechnology company that develops and commercializes serine hydrolase inhibitors for the treatment of neurological diseases... Read more
Abide is a biotechnology company that develops and commercializes serine hydrolase inhibitors for the treatment of neurological diseases... Read more
News
May 15, 2019
PharmaTech
Abide: Lundbeck to Acquire Abide Therapeutics
May 06, 2019
BioPharma Dive
Abide: Lundbeck builds out brain drug pipeline with $250M acquisition
Jan 28, 2019
Xconomy
Abide Therapeutics: Former Zavante Executive Tapped as Abide Therapeutics President
Jan 27, 2019
San Diego Business Journal
Abide Therapeutics: Abide Therapeutics Names New COO
Aug 09, 2018
BioPortfolio
Abide Therapeutics: Abide Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 12042018 Prices from USD $250
Apr 10, 2018
PR Newswire
Press Release: Abide Therapeutics : Abide Therapeutics Presents Positive Data from a Phase 1b Study of ABX-1431 in Tourette Syndrome at the American Academy of Neurology 70th Annual Meeting
Apr 04, 2018
ForImmediateRelease
Press Release: Abide Therapeutics : Abide Therapeutics Appoints Thomas C. Südhof to Board of Directors
Apr 02, 2018
BioPortfolio
Abide Therapeutics: Abide Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 19022018 Prices from USD $250
Mar 28, 2018
Reuters
Abide Therapeutics: BRIEF-Abide And Celgene Enter Worldwide License Agreement For ABX-1772
Feb 07, 2018
ForImmediateRelease
Press Release: Abide Therapeutics : Abide Therapeutics to Participate in February 2018 Investor Conferences
Abide Therapeutics, Inc. Competitors
1
2
3
4
5
6
7
8
9
10